Your browser doesn't support javascript.
Assessment of the Humoral Immune Response Following COVID-19 Vaccination in Healthcare Workers: A One Year Longitudinal Study.
Chivu-Economescu, Mihaela; Vremera, Teodora; Ruta, Simona Maria; Grancea, Camelia; Leustean, Mihaela; Chiriac, Daniela; David, Adina; Matei, Lilia; Diaconu, Carmen C; Gatea, Adina; Ilie, Ciprian; Radu, Iuliana; Cornienco, Ana Maria; Iancu, Luminita Smaranda; Cirstoiu, Catalin; Pop, Corina Silvia; Petru, Radu; Strambu, Victor; Malciolu, Stefan; Popescu, Corneliu Petru; Florescu, Simin Aysel; Rafila, Alexandru; Furtunescu, Florentina Ligia; Pistol, Adriana.
  • Chivu-Economescu M; Stefan S. Nicolau Institute of Virology, Romanian Academy, 030304 Bucharest, Romania.
  • Vremera T; National Institute of Public Health Bucharest, 050463 Bucharest, Romania.
  • Ruta SM; ECDC Fellowship Programme, Public Health Microbiology Path (EUPHEM), European Centre for Disease Prevention and Control (ECDC), 16973 Solna, Sweden.
  • Grancea C; Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania.
  • Leustean M; Stefan S. Nicolau Institute of Virology, Romanian Academy, 030304 Bucharest, Romania.
  • Chiriac D; National Institute of Public Health Bucharest, 050463 Bucharest, Romania.
  • David A; Stefan S. Nicolau Institute of Virology, Romanian Academy, 030304 Bucharest, Romania.
  • Matei L; National Institute of Public Health Bucharest, 050463 Bucharest, Romania.
  • Diaconu CC; Stefan S. Nicolau Institute of Virology, Romanian Academy, 030304 Bucharest, Romania.
  • Gatea A; Stefan S. Nicolau Institute of Virology, Romanian Academy, 030304 Bucharest, Romania.
  • Ilie C; National Institute of Public Health Bucharest, 050463 Bucharest, Romania.
  • Radu I; National Institute of Public Health Bucharest, 050463 Bucharest, Romania.
  • Cornienco AM; National Institute of Public Health Bucharest, 050463 Bucharest, Romania.
  • Iancu LS; National Institute of Public Health Bucharest, 050463 Bucharest, Romania.
  • Cirstoiu C; Faculty of Medicine, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania.
  • Pop CS; Regional Center of Public Health Iași, 700465 Iași, Romania.
  • Petru R; Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania.
  • Strambu V; University Emergency Hospital, 050098 Bucharest, Romania.
  • Malciolu S; Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania.
  • Popescu CP; University Emergency Hospital, 050098 Bucharest, Romania.
  • Florescu SA; Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania.
  • Rafila A; Dr. Carol Davila Nephrology Clinical Hospital, 010731 Bucharest, Romania.
  • Furtunescu FL; Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania.
  • Pistol A; Dr. Carol Davila Nephrology Clinical Hospital, 010731 Bucharest, Romania.
Biomedicines ; 10(7)2022 Jun 28.
Article in English | MEDLINE | ID: covidwho-1911182
ABSTRACT
The continuous variability of SARS-CoV-2 and the rapid waning of specific antibodies threatens the efficacy of COVID-19 vaccines. We aimed to evaluate antibody kinetics one year after SARS-CoV-2 vaccination with an mRNA vaccine in healthcare workers (HCW), with or without a booster. A marked decline in anti-Spike(S)/Receptor Binding Domain (RBD) antibody levels was registered during the first eight months post-vaccination, followed by a transitory increase after the booster. At three months post-booster an increased antibody level was maintained only in HCW vaccinated after a prior infection, who also developed a higher and long-lasting level of anti-S IgA antibodies. Still, IgG anti-nucleocapsid (NCP) fades five months post-SARS-CoV-2 infection. Despite the decline in antibodies one-year post-vaccination, 68.2% of HCW preserved the neutralization capacity against the ancestral variant, with a decrease of only 17.08% in the neutralizing capacity against the Omicron variant. Nevertheless, breakthrough infections were present in 6.65% of all participants, without any correlation with the previous level of anti-S/RBD IgG. Protection against the ancestral and Omicron variants is maintained at least three months after a booster in HCW, possibly reflecting a continuous antigenic stimulation in the professional setting.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Topics: Vaccines / Variants Language: English Year: 2022 Document Type: Article Affiliation country: Biomedicines10071526

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Topics: Vaccines / Variants Language: English Year: 2022 Document Type: Article Affiliation country: Biomedicines10071526